John Gong

机构：Western Digital (China)

发表论文 11 篇 · 总被引 316 次 · h-index 6

代表论文

Subcutaneous envafolimab monotherapy in patients with advanced defective mismatch repair/microsatellite instability high solid tumors (2021 · Journal of Hematology & Oncology · 被引 150)
First-in-Human Phase I Study of Envafolimab, a Novel Subcutaneous Single-Domain Anti-PD-L1 Antibody, in Patients with Advanced Solid Tumors (2021 · The Oncologist · 被引 78)
Phase I study of envafolimab (KN035), a novel subcutaneous single-domain anti-PD-L1 monoclonal antibody, in Japanese patients with advanced solid tumors (2022 · Investigational New Drugs · 被引 53)
Phase I study of KN035, the first subcutaneously administered, novel fusion anti-PD-L1 antibody in patients with advanced solid tumors in China. (2019 · Journal of Clinical Oncology · 被引 13)
Phase I safety and pharmacokinetic study of KN035, the first subcutaneously administered, novel fusion anti-PD-L1 antibody in Japanese patients with advanced solid tumors. (2019 · Journal of Clinical Oncology · 被引 7)
Envafolimab plus chemotherapy in advanced gastric or gastroesophageal junction (G/GEJ) cancer. (2020 · Journal of Clinical Oncology · 被引 6)